SYNTEKABIO, INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 9,730 KRW | -2.41% |
|
-3.38% | -31.67% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
| Sales 2022 | 244M 181K | Sales 2023 | 123M 91.32K | Capitalization | 217B 160M |
|---|---|---|---|---|---|
| Net income 2022 | -4.51B -3.33M | Net income 2023 | -11.4B -8.43M | EV / Sales 2022 | 376 x |
| Net cash position 2022 | 24.22B 17.92M | Net cash position 2023 | 17.57B 13M | EV / Sales 2023 | 1,615 x |
| P/E ratio 2022 |
-25.7
x | P/E ratio 2023 |
-17.9
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 80.21% |
More Fundamentals
* Assessed data
More news
| 1 day | -2.41% | ||
| 1 week | -3.38% | ||
| Current month | -4.61% | ||
| 1 month | -5.53% | ||
| 3 months | -27.50% | ||
| 6 months | -6.26% | ||
| Current year | -31.67% |
1 week
9 500.00
10 200.00
1 month
9 500.0011 100.00
Current year
9 150.0014 700.00
1 year
7 510.0019 960.00
3 years
7 200.0022 050.00
5 years
5 010.0048 700.00
10 years
5 010.0048 700.00
| Managers | Title | Age | Since |
|---|---|---|---|
Tyson Kim
CEO | Chief Executive Officer | - | 14-12-31 |
Jongsun Jung
FOU | Founder | - | 08-12-31 |
Sunghoon Park
DFI | Director of Finance/CFO | - | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-17 | 9,730 | -2.41% | 50,243 |
| 24-05-16 | 9,970 | +1.01% | 48,578 |
| 24-05-14 | 9,870 | +2.39% | 48,577 |
| 24-05-13 | 9,640 | -4.27% | 129,342 |
| 24-05-10 | 10,070 | -1.08% | 52,200 |
End-of-day quote Korea S.E., May 16, 2024
More quotes
Syntekabio,Inc. is a Korea-based company principally engaged in the provision of database and software. The Company develops and sells software such as personal algorithm dielectric map platform (PMAP) using artificial intelligence (AI) technology, provides clinical trial modeling and genome analysis services through big data. The analysis results are used to diagnose genetic diseases, select biomarker treatments and predict disease risk. In addition, the Company develops AI drug development technology, provides research services for candidate substances of immuno-cancer drugs.
Sector
Software
Calendar
2024-08-12
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -31.67% | 110M | |
| -9.30% | 27.2B | |
| +22.47% | 1.38B |
- Stock Market
- Equities
- A226330 Stock
